Search results for "Generic drug"

showing 4 items of 4 documents

Patterns and trends in scientific research on generic drugs

2016

[Purpose]: The purpose of this study to investigate the evolution and current status of peer-reviewed publications concerning generic drugs during the past few decades. [Methods]: Scientific articles about generic drugs published until 2012 were retrieved through the PubMed/MEDLINE database, and a content analysis was performed. [Findings]: Our study revealed an increasing number of publications on generics since 1984. Statins, antiretroviral therapies, and antiepileptics, followed by immunosuppressants and antithrombotic agents, were the most common therapeutic drug categories. [Implications]: Almost 60% of the generics detailed in studies indexed in MEDLINE were acting on the cardiovascul…

Drugmedicine.medical_specialtyATC classification systemmedia_common.quotation_subjectAlternative medicineMEDLINEPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineAntithromboticmedicineDrugs GenericHumansGeneric drugsPharmacology (medical)030212 general & internal medicineIntensive care medicinemedia_commonPharmacologyPeer Review Researchbusiness.industryResearchDrugs genericPubMed/MedlinePeriodicals as TopicMedline databasebusinessContent analysis
researchProduct

Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study

2019

The patients’ persistence with osteoporosis treatments is low. This retrospective, multicenter survey showed that almost 30% of osteoporotic patients discontinued the treatment within the first 6 months and that those taking drinkable bisphosphonates were less likely to interrupt the therapy; instead, the use of generic bisphosphonates was associated to a more precocious interruption. Purpose: Low persistence with osteoporosis medications is associated with higher fracture risk. This study aimed to assess the persistence to treatment with oral bisphosphonates among Italian osteoporotic patients under treatment for at least 6 months and to evaluate whether the different oral formulations of …

MaleAgingmedicine.medical_specialtyGeneric drugmedicine.medical_treatmentOsteoporosisDrinkable bisphosphonates; Generic drug; Oral bisphosphonates; Osteoporosis; PersistenceAdministration OralPersistence (computer science)Medication AdherencePersistence03 medical and health sciencesFractures Bone0302 clinical medicineInternal medicineGeneric drugmedicineHumansDrinkable bisphosphonatesGeneric drugOral bisphosphonatesOsteoporosisPersistence030212 general & internal medicineMedical prescriptionAdverse effectAgedRetrospective StudiesOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryOral bisphosphonatesSettore MED/34 - Medicina Fisica E RiabilitativaBisphosphonateMiddle Agedmedicine.diseaseDiscontinuationLogistic ModelsItalyCase-Control StudiesOsteoporosisFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryOsteoporotic FracturesDrinkable bisphosphonates
researchProduct

Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy.

2011

The demonstration of bioequivalence (BE) is an essential requirement for ensuring that patients receive a product that performs as indicated by the label. The BE standard for a particular product is set by its innovator, and this standard must subsequently be matched by generic drug products. The Biopharmaceutics Classification System (BCS) sets a scientific basis for an improved BE standard for immediate-release solid oral dosage forms. In this paper, we discuss BE and the BCS, as well as the issues that are currently relevant to BE as a pharmaceutical product standard.

Pharmacologybusiness.industryBiopharmaceuticsPublic policyAdministration OralBioequivalencePharmacologyBiopharmaceutics Classification SystemhumanitiesArticleBiopharmaceuticsPolicyRisk analysis (engineering)Pharmaceutical PreparationsTherapeutic EquivalencyInnovatorGeneric drugMedicineDrugs GenericHumansPharmacology (medical)Product (category theory)Product standardbusinessClinical pharmacology and therapeutics
researchProduct

Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate

2021

Complex iron nanoparticle-based drugs are one of the oldest and most frequently administered classes of nanomedicines. In the US, there are seven FDA-approved iron nanoparticle reference drug products, of which one also has an approved generic drug product (i.e., sodium ferric gluconate (SFG)). These products are indicated for the treatment of iron deficiency anemia and are administered intravenously. On the molecular level, iron nanomedicines are colloids composed of an iron oxide core with a carbohydrate coating. This formulation makes nanomedicines more complex than conventional small molecule drugs. As such, these products are often referred to as nonbiological complex drugs (e.g., by t…

Quality ControlDrugChemistry Pharmaceuticalmedia_common.quotation_subjectIron oxidePharmaceutical ScienceEquivalence Trials as Topic02 engineering and technologyFerric Compounds030226 pharmacology & pharmacyGel permeation chromatography03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsDynamic light scatteringGeneric drugDrug DiscoveryDrugs GenericHumansInductively coupled plasma mass spectrometrymedia_commonAnemia Iron-Deficiency021001 nanoscience & nanotechnologySmall moleculeDynamic Light ScatteringchemistryChromatography GelNanoparticlesMolecular Medicine0210 nano-technologyUltracentrifugationNuclear chemistryMolecular Pharmaceutics
researchProduct